ClinVar Miner

Submissions for variant NM_003242.6(TGFBR2):c.907A>C (p.Asn303His)

dbSNP: rs773932892
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000799279 SCV000938934 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2022-07-05 criteria provided, single submitter clinical testing This sequence change replaces asparagine, which is neutral and polar, with histidine, which is basic and polar, at codon 303 of the TGFBR2 protein (p.Asn303His). This variant is present in population databases (rs773932892, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with TGFBR2-related conditions. ClinVar contains an entry for this variant (Variation ID: 645234). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TGFBR2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV000799279 SCV002042885 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2020-06-08 criteria provided, single submitter clinical testing
Ambry Genetics RCV000799279 SCV002684669 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2022-08-07 criteria provided, single submitter clinical testing The p.N303H variant (also known as c.907A>C), located in coding exon 4 of the TGFBR2 gene, results from an A to C substitution at nucleotide position 907. The asparagine at codon 303 is replaced by histidine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
PreventionGenetics, part of Exact Sciences RCV003413599 SCV004114542 uncertain significance TGFBR2-related condition 2022-12-31 criteria provided, single submitter clinical testing The TGFBR2 c.907A>C variant is predicted to result in the amino acid substitution p.Asn303His. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/3-30713582-A-C). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.